Addendum: Liquid biopsy and multi-analyte testing guided treatment of  HER2  positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy

Rajnish Nagarkar; Darshana Patil; Sewanti Limaye; Pradip Devhare; Ashwini Ghaisas; Navin Srivastava; Sachin Apurwa; Sanket Patil; Jinumary John; Zarrine Raazi; Aditya Shreenivas; Janani Sambath; Ajay Srinivasan; Prashant Kumar; Dadasaheb Akolkar; Rajan Datar

doi:10.18632/oncotarget.28296

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: Liquid biopsy and multi-analyte testing guided treatment of HER2 positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy

PDF | How to cite

Oncotarget. 2022; 13:1215-1215. https://doi.org/10.18632/oncotarget.28296

Metrics: PDF 664 views | ?

Rajnish Nagarkar¹, Darshana Patil², Sewanti Limaye³, Pradip Devhare², Ashwini Ghaisas², Navin Srivastava², Sachin Apurwa², Sanket Patil², Jinumary John², Zarrine Raazi², Aditya Shreenivas⁴, Janani Sambath^5,6, Ajay Srinivasan², Prashant Kumar^2,5,6, Dadasaheb Akolkar² and Rajan Datar²

¹HCG Manavata Cancer Centre, Nasik, Maharashtra, India
²Datar Cancer Genetics Limited, Nasik, Maharashtra, India
³Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, Maharashtra, India
⁴Department of Medical Oncology, Medical College Wisconsin, WI, USA
⁵Institute of Bioinformatics, International Technology Park, Bangalore, Karnataka, India
⁶Manipal Academy of Higher Education, Manipal, Karnataka, India

Published: November 2, 2022

Copyright: © 2022 Nagarkar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: The patient has previously consented to publication of de-identified findings.

Original article: Oncotarget. 2020; 11:4195–4200. DOI: https://doi.org/10.18632/oncotarget.27793

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28296

Publication Alerts

Post-Publication Promotion

Publication Discount

Addendum:

Addendum: Liquid biopsy and multi-analyte testing guided treatment of HER2 positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy